Loading…
Autophagy and cancer drug resistance in dialogue: Pre-clinical and clinical evidence
The emergence of drug resistance is a major challenge for oncologists. Resistance can be categorized as acquired or intrinsic; the alteration of several biological mechanisms contributes to both intrinsic and acquired resistance. Macroautophagy/autophagy is the primary process in eukaryotes for the...
Saved in:
Published in: | Cancer letters 2023-08, Vol.570, p.216307-216307, Article 216307 |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c362t-c51b628c3d25bfa3e40e48f2c07d592d0a257e470d045f699fd23fa7a42606da3 |
---|---|
cites | cdi_FETCH-LOGICAL-c362t-c51b628c3d25bfa3e40e48f2c07d592d0a257e470d045f699fd23fa7a42606da3 |
container_end_page | 216307 |
container_issue | |
container_start_page | 216307 |
container_title | Cancer letters |
container_volume | 570 |
creator | Qin, Yi Ashrafizadeh, Milad Mongiardini, Vera Grimaldi, Benedetto Crea, Francesco Rietdorf, Katja Győrffy, Balázs Klionsky, Daniel J. Ren, Jun Zhang, Wei Zhang, Xianbin |
description | The emergence of drug resistance is a major challenge for oncologists. Resistance can be categorized as acquired or intrinsic; the alteration of several biological mechanisms contributes to both intrinsic and acquired resistance. Macroautophagy/autophagy is the primary process in eukaryotes for the degradation of macromolecules and organelles. This process is critical in maintaining cellular homeostasis. Given its function as either a pro-survival or a pro-death phenomenon, autophagy has a complex physio-pathological role. In some circumstances, autophagy can confer chemoresistance and promote cell survival, whereas in others it can promote chemosensitivity and contribute to cell death. The role of autophagy in the modulation of cancer drug resistance reflects its impact on apoptosis and metastasis. The regulation of autophagy in cancer is mediated by various factors including AMP-activated protein kinase (AMPK), MAPK, phosphoinositide 3-kinase (PI3K)-AKT, BECN1 and ATG proteins. Non-coding RNAs are among the main regulators of autophagy, e.g., via the modulation of chemoresistance pathways. Due to the significant contribution of autophagy in cancer drug resistance, small molecule modulators and natural compounds targeting autophagy have been introduced to alter the response of cancer cells to chemotherapy. Furthermore, nanotherapeutic approaches based on autophagy regulation have been introduced in pre-clinical cancer therapy. In this review we consider the potential for using autophagy regulators for the clinical treatment of malignancies.
[Display omitted]
•Cancer drug resistance is a main cause of therapeutic failure in cancer patients.•Autophagy can enhance drug resistance by inhibiting apoptosis and promoting metastasis.•Autophagy modulators can counteract cancer drug resistance.•Nanostructure-mediated autophagy regulation affects drug resistance.•Non-coding RNA-mediated autophagy can alleviate drug resistance. |
doi_str_mv | 10.1016/j.canlet.2023.216307 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2838253280</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0304383523002586</els_id><sourcerecordid>2838253280</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-c51b628c3d25bfa3e40e48f2c07d592d0a257e470d045f699fd23fa7a42606da3</originalsourceid><addsrcrecordid>eNp9kE1Lw0AQhhdRbK3-A5EcvaRO9iObeBBK8QsKeqjnZbs7qVvSpO4mhf57E9J69DTs8Lwzsw8htwlME0jSh83U6KrEZkqBsilNUgbyjIyTTNJY5hmckzEw4DHLmBiRqxA2ACC4FJdkxCQXCafpmCxnbVPvvvX6EOnKRt1Igz6yvl1HHoMLTd-IXBVZp8t63eJj9OkxNqWrnNHlEDo9cO8sdvw1uSh0GfDmWCfk6-V5OX-LFx-v7_PZIjYspU1sRLJKaWaYpWJVaIYckGcFNSCtyKkFTYVELsECF0Wa54WlrNBSd5dDajWbkPth7s7XPy2GRm1dMFiWusK6DYpmLKOC0Qw6lA-o8XUIHgu1826r_UEloHqfaqMGn6r3qQafXezuuKFdbdH-hU4CO-BpALD7596hV8G43oF1Hk2jbO3-3_ALJNmH6g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2838253280</pqid></control><display><type>article</type><title>Autophagy and cancer drug resistance in dialogue: Pre-clinical and clinical evidence</title><source>Elsevier</source><creator>Qin, Yi ; Ashrafizadeh, Milad ; Mongiardini, Vera ; Grimaldi, Benedetto ; Crea, Francesco ; Rietdorf, Katja ; Győrffy, Balázs ; Klionsky, Daniel J. ; Ren, Jun ; Zhang, Wei ; Zhang, Xianbin</creator><creatorcontrib>Qin, Yi ; Ashrafizadeh, Milad ; Mongiardini, Vera ; Grimaldi, Benedetto ; Crea, Francesco ; Rietdorf, Katja ; Győrffy, Balázs ; Klionsky, Daniel J. ; Ren, Jun ; Zhang, Wei ; Zhang, Xianbin</creatorcontrib><description>The emergence of drug resistance is a major challenge for oncologists. Resistance can be categorized as acquired or intrinsic; the alteration of several biological mechanisms contributes to both intrinsic and acquired resistance. Macroautophagy/autophagy is the primary process in eukaryotes for the degradation of macromolecules and organelles. This process is critical in maintaining cellular homeostasis. Given its function as either a pro-survival or a pro-death phenomenon, autophagy has a complex physio-pathological role. In some circumstances, autophagy can confer chemoresistance and promote cell survival, whereas in others it can promote chemosensitivity and contribute to cell death. The role of autophagy in the modulation of cancer drug resistance reflects its impact on apoptosis and metastasis. The regulation of autophagy in cancer is mediated by various factors including AMP-activated protein kinase (AMPK), MAPK, phosphoinositide 3-kinase (PI3K)-AKT, BECN1 and ATG proteins. Non-coding RNAs are among the main regulators of autophagy, e.g., via the modulation of chemoresistance pathways. Due to the significant contribution of autophagy in cancer drug resistance, small molecule modulators and natural compounds targeting autophagy have been introduced to alter the response of cancer cells to chemotherapy. Furthermore, nanotherapeutic approaches based on autophagy regulation have been introduced in pre-clinical cancer therapy. In this review we consider the potential for using autophagy regulators for the clinical treatment of malignancies.
[Display omitted]
•Cancer drug resistance is a main cause of therapeutic failure in cancer patients.•Autophagy can enhance drug resistance by inhibiting apoptosis and promoting metastasis.•Autophagy modulators can counteract cancer drug resistance.•Nanostructure-mediated autophagy regulation affects drug resistance.•Non-coding RNA-mediated autophagy can alleviate drug resistance.</description><identifier>ISSN: 0304-3835</identifier><identifier>EISSN: 1872-7980</identifier><identifier>DOI: 10.1016/j.canlet.2023.216307</identifier><identifier>PMID: 37451426</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Apoptosis ; Autophagy ; Cancer drug resistance ; Cell death ; Chemoresistance ; Drug sensitivity</subject><ispartof>Cancer letters, 2023-08, Vol.570, p.216307-216307, Article 216307</ispartof><rights>2023 Elsevier B.V.</rights><rights>Copyright © 2023. Published by Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-c51b628c3d25bfa3e40e48f2c07d592d0a257e470d045f699fd23fa7a42606da3</citedby><cites>FETCH-LOGICAL-c362t-c51b628c3d25bfa3e40e48f2c07d592d0a257e470d045f699fd23fa7a42606da3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37451426$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Qin, Yi</creatorcontrib><creatorcontrib>Ashrafizadeh, Milad</creatorcontrib><creatorcontrib>Mongiardini, Vera</creatorcontrib><creatorcontrib>Grimaldi, Benedetto</creatorcontrib><creatorcontrib>Crea, Francesco</creatorcontrib><creatorcontrib>Rietdorf, Katja</creatorcontrib><creatorcontrib>Győrffy, Balázs</creatorcontrib><creatorcontrib>Klionsky, Daniel J.</creatorcontrib><creatorcontrib>Ren, Jun</creatorcontrib><creatorcontrib>Zhang, Wei</creatorcontrib><creatorcontrib>Zhang, Xianbin</creatorcontrib><title>Autophagy and cancer drug resistance in dialogue: Pre-clinical and clinical evidence</title><title>Cancer letters</title><addtitle>Cancer Lett</addtitle><description>The emergence of drug resistance is a major challenge for oncologists. Resistance can be categorized as acquired or intrinsic; the alteration of several biological mechanisms contributes to both intrinsic and acquired resistance. Macroautophagy/autophagy is the primary process in eukaryotes for the degradation of macromolecules and organelles. This process is critical in maintaining cellular homeostasis. Given its function as either a pro-survival or a pro-death phenomenon, autophagy has a complex physio-pathological role. In some circumstances, autophagy can confer chemoresistance and promote cell survival, whereas in others it can promote chemosensitivity and contribute to cell death. The role of autophagy in the modulation of cancer drug resistance reflects its impact on apoptosis and metastasis. The regulation of autophagy in cancer is mediated by various factors including AMP-activated protein kinase (AMPK), MAPK, phosphoinositide 3-kinase (PI3K)-AKT, BECN1 and ATG proteins. Non-coding RNAs are among the main regulators of autophagy, e.g., via the modulation of chemoresistance pathways. Due to the significant contribution of autophagy in cancer drug resistance, small molecule modulators and natural compounds targeting autophagy have been introduced to alter the response of cancer cells to chemotherapy. Furthermore, nanotherapeutic approaches based on autophagy regulation have been introduced in pre-clinical cancer therapy. In this review we consider the potential for using autophagy regulators for the clinical treatment of malignancies.
[Display omitted]
•Cancer drug resistance is a main cause of therapeutic failure in cancer patients.•Autophagy can enhance drug resistance by inhibiting apoptosis and promoting metastasis.•Autophagy modulators can counteract cancer drug resistance.•Nanostructure-mediated autophagy regulation affects drug resistance.•Non-coding RNA-mediated autophagy can alleviate drug resistance.</description><subject>Apoptosis</subject><subject>Autophagy</subject><subject>Cancer drug resistance</subject><subject>Cell death</subject><subject>Chemoresistance</subject><subject>Drug sensitivity</subject><issn>0304-3835</issn><issn>1872-7980</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kE1Lw0AQhhdRbK3-A5EcvaRO9iObeBBK8QsKeqjnZbs7qVvSpO4mhf57E9J69DTs8Lwzsw8htwlME0jSh83U6KrEZkqBsilNUgbyjIyTTNJY5hmckzEw4DHLmBiRqxA2ACC4FJdkxCQXCafpmCxnbVPvvvX6EOnKRt1Igz6yvl1HHoMLTd-IXBVZp8t63eJj9OkxNqWrnNHlEDo9cO8sdvw1uSh0GfDmWCfk6-V5OX-LFx-v7_PZIjYspU1sRLJKaWaYpWJVaIYckGcFNSCtyKkFTYVELsECF0Wa54WlrNBSd5dDajWbkPth7s7XPy2GRm1dMFiWusK6DYpmLKOC0Qw6lA-o8XUIHgu1826r_UEloHqfaqMGn6r3qQafXezuuKFdbdH-hU4CO-BpALD7596hV8G43oF1Hk2jbO3-3_ALJNmH6g</recordid><startdate>20230828</startdate><enddate>20230828</enddate><creator>Qin, Yi</creator><creator>Ashrafizadeh, Milad</creator><creator>Mongiardini, Vera</creator><creator>Grimaldi, Benedetto</creator><creator>Crea, Francesco</creator><creator>Rietdorf, Katja</creator><creator>Győrffy, Balázs</creator><creator>Klionsky, Daniel J.</creator><creator>Ren, Jun</creator><creator>Zhang, Wei</creator><creator>Zhang, Xianbin</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20230828</creationdate><title>Autophagy and cancer drug resistance in dialogue: Pre-clinical and clinical evidence</title><author>Qin, Yi ; Ashrafizadeh, Milad ; Mongiardini, Vera ; Grimaldi, Benedetto ; Crea, Francesco ; Rietdorf, Katja ; Győrffy, Balázs ; Klionsky, Daniel J. ; Ren, Jun ; Zhang, Wei ; Zhang, Xianbin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-c51b628c3d25bfa3e40e48f2c07d592d0a257e470d045f699fd23fa7a42606da3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Apoptosis</topic><topic>Autophagy</topic><topic>Cancer drug resistance</topic><topic>Cell death</topic><topic>Chemoresistance</topic><topic>Drug sensitivity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Qin, Yi</creatorcontrib><creatorcontrib>Ashrafizadeh, Milad</creatorcontrib><creatorcontrib>Mongiardini, Vera</creatorcontrib><creatorcontrib>Grimaldi, Benedetto</creatorcontrib><creatorcontrib>Crea, Francesco</creatorcontrib><creatorcontrib>Rietdorf, Katja</creatorcontrib><creatorcontrib>Győrffy, Balázs</creatorcontrib><creatorcontrib>Klionsky, Daniel J.</creatorcontrib><creatorcontrib>Ren, Jun</creatorcontrib><creatorcontrib>Zhang, Wei</creatorcontrib><creatorcontrib>Zhang, Xianbin</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Qin, Yi</au><au>Ashrafizadeh, Milad</au><au>Mongiardini, Vera</au><au>Grimaldi, Benedetto</au><au>Crea, Francesco</au><au>Rietdorf, Katja</au><au>Győrffy, Balázs</au><au>Klionsky, Daniel J.</au><au>Ren, Jun</au><au>Zhang, Wei</au><au>Zhang, Xianbin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Autophagy and cancer drug resistance in dialogue: Pre-clinical and clinical evidence</atitle><jtitle>Cancer letters</jtitle><addtitle>Cancer Lett</addtitle><date>2023-08-28</date><risdate>2023</risdate><volume>570</volume><spage>216307</spage><epage>216307</epage><pages>216307-216307</pages><artnum>216307</artnum><issn>0304-3835</issn><eissn>1872-7980</eissn><abstract>The emergence of drug resistance is a major challenge for oncologists. Resistance can be categorized as acquired or intrinsic; the alteration of several biological mechanisms contributes to both intrinsic and acquired resistance. Macroautophagy/autophagy is the primary process in eukaryotes for the degradation of macromolecules and organelles. This process is critical in maintaining cellular homeostasis. Given its function as either a pro-survival or a pro-death phenomenon, autophagy has a complex physio-pathological role. In some circumstances, autophagy can confer chemoresistance and promote cell survival, whereas in others it can promote chemosensitivity and contribute to cell death. The role of autophagy in the modulation of cancer drug resistance reflects its impact on apoptosis and metastasis. The regulation of autophagy in cancer is mediated by various factors including AMP-activated protein kinase (AMPK), MAPK, phosphoinositide 3-kinase (PI3K)-AKT, BECN1 and ATG proteins. Non-coding RNAs are among the main regulators of autophagy, e.g., via the modulation of chemoresistance pathways. Due to the significant contribution of autophagy in cancer drug resistance, small molecule modulators and natural compounds targeting autophagy have been introduced to alter the response of cancer cells to chemotherapy. Furthermore, nanotherapeutic approaches based on autophagy regulation have been introduced in pre-clinical cancer therapy. In this review we consider the potential for using autophagy regulators for the clinical treatment of malignancies.
[Display omitted]
•Cancer drug resistance is a main cause of therapeutic failure in cancer patients.•Autophagy can enhance drug resistance by inhibiting apoptosis and promoting metastasis.•Autophagy modulators can counteract cancer drug resistance.•Nanostructure-mediated autophagy regulation affects drug resistance.•Non-coding RNA-mediated autophagy can alleviate drug resistance.</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>37451426</pmid><doi>10.1016/j.canlet.2023.216307</doi><tpages>1</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0304-3835 |
ispartof | Cancer letters, 2023-08, Vol.570, p.216307-216307, Article 216307 |
issn | 0304-3835 1872-7980 |
language | eng |
recordid | cdi_proquest_miscellaneous_2838253280 |
source | Elsevier |
subjects | Apoptosis Autophagy Cancer drug resistance Cell death Chemoresistance Drug sensitivity |
title | Autophagy and cancer drug resistance in dialogue: Pre-clinical and clinical evidence |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T13%3A26%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Autophagy%20and%20cancer%20drug%20resistance%20in%20dialogue:%20Pre-clinical%20and%20clinical%20evidence&rft.jtitle=Cancer%20letters&rft.au=Qin,%20Yi&rft.date=2023-08-28&rft.volume=570&rft.spage=216307&rft.epage=216307&rft.pages=216307-216307&rft.artnum=216307&rft.issn=0304-3835&rft.eissn=1872-7980&rft_id=info:doi/10.1016/j.canlet.2023.216307&rft_dat=%3Cproquest_cross%3E2838253280%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c362t-c51b628c3d25bfa3e40e48f2c07d592d0a257e470d045f699fd23fa7a42606da3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2838253280&rft_id=info:pmid/37451426&rfr_iscdi=true |